Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 1/2012

01-01-2012 | Original Article

Variability in the clinical management of fatty acid oxidation disorders: results of a survey of Canadian metabolic physicians

Authors: Beth K. Potter, Julian Little, Pranesh Chakraborty, Jonathan B. Kronick, Jessica Evans, Julia Frei, Sarah C. Sutherland, Kumanan Wilson, Brenda J. Wilson

Published in: Journal of Inherited Metabolic Disease | Issue 1/2012

Login to get access

Abstract

Introduction

There is little robust empirical evidence on which to base treatment recommendations for fatty acid oxidation disorders. While consensus guidelines are important, understanding areas where there is a lack of consensus is also critical to inform priorities for future evaluative research.

Methods

We surveyed Canadian metabolic physicians on the treatment of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency, long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, and mitochondrial trifunctional protein (MTP) deficiency. We ascertained physicians’ opinions on the use of different interventions for the long-term management of patients as well as for the management of acute illness, focusing on identifying interventions characterized by high variability in opinions. We also investigated factors influencing treatment decisions.

Results

We received 18 responses (response rate 45%). Participants focused on avoidance of fasting and increased meal frequency as interventions for the management of MCAD deficiency. For the long-chain disorders, avoidance of fasting remained the most consistently endorsed intervention, with additional highly endorsed treatments differing for VLCAD versus LCHAD/MTP deficiency. L-carnitine supplementation and restriction of dietary fat were characterized by high variability in physicians’ opinions, as were several interventions specific to long-chain disorders. Social factors and patient characteristics were important influences on treatment decisions.

Conclusions

Based on our findings we suggest that high priority treatments for rigorous effectiveness studies could include L-carnitine supplementation (MCAD and LCHAD/MTP deficiencies), restriction of dietary fat, and, for the long-chain disorders, feeding practices for breastfed infants and the use of various supplements (essential fatty acids, carbohydrates, cornstarch, multivitamins).
Literature
go back to reference Arnold GL, VanHove J, Freedenberg D et al. (2009) A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency. Mol Genet Metab 96:85–90PubMedCrossRef Arnold GL, VanHove J, Freedenberg D et al. (2009) A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency. Mol Genet Metab 96:85–90PubMedCrossRef
go back to reference Arnold GL, Saavedra-Matiz CA, Galvin-Parton PA et al. (2010) Lack of genotype-phenotype correlations and outcome in MCAD deficiency diagnosed by newborn screening in New York State. Mol Genet Metab 99:263–268PubMedCrossRef Arnold GL, Saavedra-Matiz CA, Galvin-Parton PA et al. (2010) Lack of genotype-phenotype correlations and outcome in MCAD deficiency diagnosed by newborn screening in New York State. Mol Genet Metab 99:263–268PubMedCrossRef
go back to reference Clancy C, Collins FS (2010) Patient-centred outcomes research institute: the intersection of science and health care. Sci Transl Med 2:37cm18 Clancy C, Collins FS (2010) Patient-centred outcomes research institute: the intersection of science and health care. Sci Transl Med 2:37cm18
go back to reference Dillman DA (2007) Mail and Internet Surveys. The Tailored Design Method. 2nd ed, 2007 update. New York: Wiley, Inc Dillman DA (2007) Mail and Internet Surveys. The Tailored Design Method. 2nd ed, 2007 update. New York: Wiley, Inc
go back to reference Djouadi F, Aubey F, Schlemmer D et al. (2005) Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders. Hum Mol Genet 14:2695–2703PubMedCrossRef Djouadi F, Aubey F, Schlemmer D et al. (2005) Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders. Hum Mol Genet 14:2695–2703PubMedCrossRef
go back to reference Djouadi F, Aubey F, Schlemmer D et al. (2006) Potential of fibrates in the treatment of fatty acid oxidation disorders: revival of classical drugs? J Inherit Metab Dis 29:341–342PubMedCrossRef Djouadi F, Aubey F, Schlemmer D et al. (2006) Potential of fibrates in the treatment of fatty acid oxidation disorders: revival of classical drugs? J Inherit Metab Dis 29:341–342PubMedCrossRef
go back to reference Gillingham MB, Scott B, Elliott D, Harding CO (2006) Metabolic control during exercise with and without medium-chain triglycerides (MCT) in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency. Mol Genet Metab 89:58–63PubMedCrossRef Gillingham MB, Scott B, Elliott D, Harding CO (2006) Metabolic control during exercise with and without medium-chain triglycerides (MCT) in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency. Mol Genet Metab 89:58–63PubMedCrossRef
go back to reference Gillingham MB, Purnell JQ, Jordan J, Stadler D, Haqq AM, Harding CO (2007) Effects of higher dietary protein intake on energy balance and metabolic control in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency. Mol Genet Metab 90:64–69PubMedCrossRef Gillingham MB, Purnell JQ, Jordan J, Stadler D, Haqq AM, Harding CO (2007) Effects of higher dietary protein intake on energy balance and metabolic control in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency. Mol Genet Metab 90:64–69PubMedCrossRef
go back to reference Griggs RC, Batshaw M, Dunkle M et al. (2009) For the rare diseases clinical research network, Clinical research for rare disease: Opportunities, challenges, and solutions. Mol Genet Metab 96:20–26PubMedCrossRef Griggs RC, Batshaw M, Dunkle M et al. (2009) For the rare diseases clinical research network, Clinical research for rare disease: Opportunities, challenges, and solutions. Mol Genet Metab 96:20–26PubMedCrossRef
go back to reference Kemper AR, Boyle CA, Aceves J et al. (2008) Long-term follow-up after diagnosis resulting from newborn screening: Statement of the US Secretary of Health and Human Services’ Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children. Genet Med 10:259–261PubMedCrossRef Kemper AR, Boyle CA, Aceves J et al. (2008) Long-term follow-up after diagnosis resulting from newborn screening: Statement of the US Secretary of Health and Human Services’ Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children. Genet Med 10:259–261PubMedCrossRef
go back to reference Laforêt P, Vianey-Saban C (2010) Disorders of muscle lipid metabolism: diagnostic and therapeutic challenges. Neuromuscul Disord 20:693–700PubMedCrossRef Laforêt P, Vianey-Saban C (2010) Disorders of muscle lipid metabolism: diagnostic and therapeutic challenges. Neuromuscul Disord 20:693–700PubMedCrossRef
go back to reference Leonard JV (2006) Komrower lecture: Treatment of inborn errors of metabolism: A review. J Inherit Metab Dis 29:275–278PubMedCrossRef Leonard JV (2006) Komrower lecture: Treatment of inborn errors of metabolism: A review. J Inherit Metab Dis 29:275–278PubMedCrossRef
go back to reference Nasser M, Javaheri H, Fedorowicz Z, Noorani Z (2009) Carnitine supplementation for inborn errors of metabolism. Cochrane Database of Systematic Reviews. Issue 2. CD006659 Nasser M, Javaheri H, Fedorowicz Z, Noorani Z (2009) Carnitine supplementation for inborn errors of metabolism. Cochrane Database of Systematic Reviews. Issue 2. CD006659
go back to reference Roe CR, Sweetman L, Roe DS, David F, Brunengraber H (2002) Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest 110:259–269PubMed Roe CR, Sweetman L, Roe DS, David F, Brunengraber H (2002) Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest 110:259–269PubMed
go back to reference Roe CR, Roe DS, Wallace M, Garritson B (2007) Choice of oils for essential fat supplements can enhance production of abnormal metabolites in fat oxidation disorders. Mol Genet Metab 92:346–350PubMedCrossRef Roe CR, Roe DS, Wallace M, Garritson B (2007) Choice of oils for essential fat supplements can enhance production of abnormal metabolites in fat oxidation disorders. Mol Genet Metab 92:346–350PubMedCrossRef
go back to reference Solis JO, Singh RH (2002) Management of fatty acid oxidation disorders: a survey of current treatment strategies. J Am Diet Assoc 102:1800–1803PubMedCrossRef Solis JO, Singh RH (2002) Management of fatty acid oxidation disorders: a survey of current treatment strategies. J Am Diet Assoc 102:1800–1803PubMedCrossRef
go back to reference Spiekerkoetter U, Lindner M, Santer R et al. (2009a) Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop. J Inherit Metab Dis 32:498–505PubMedCrossRef Spiekerkoetter U, Lindner M, Santer R et al. (2009a) Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop. J Inherit Metab Dis 32:498–505PubMedCrossRef
go back to reference Spiekerkoetter U, Lindner M, Santer R et al. (2009b) Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop. J Inherit Metab Dis 32:488–497PubMedCrossRef Spiekerkoetter U, Lindner M, Santer R et al. (2009b) Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop. J Inherit Metab Dis 32:488–497PubMedCrossRef
go back to reference Spiekerkoetter U, Bastin J, Gillingham M, Morris A, Wijburg F, Wilcken B (2010) Current issues regarding treatment of mitochondrial fatty acid oxidation disorders. J Inherit Metab Dis 33:555–561PubMedCrossRef Spiekerkoetter U, Bastin J, Gillingham M, Morris A, Wijburg F, Wilcken B (2010) Current issues regarding treatment of mitochondrial fatty acid oxidation disorders. J Inherit Metab Dis 33:555–561PubMedCrossRef
go back to reference Steiner RD (2005) Evidence based medicine in inborn errors of metabolism: Is there any and how to find it. Am J Med Genet 134A:192–197PubMedCrossRef Steiner RD (2005) Evidence based medicine in inborn errors of metabolism: Is there any and how to find it. Am J Med Genet 134A:192–197PubMedCrossRef
go back to reference VanGeest JB, Johnson TP, Welc VL (2007) Methodologies for improving response rates in surveys of physicians: A systematic review. Eval Health Prof 30:303–321PubMedCrossRef VanGeest JB, Johnson TP, Welc VL (2007) Methodologies for improving response rates in surveys of physicians: A systematic review. Eval Health Prof 30:303–321PubMedCrossRef
go back to reference Vockley J, Vockley CMW (2010) Clinical trials: Curing a critical deficiency in metabolic medicine. Mol Genet Metab 99:244–245PubMedCrossRef Vockley J, Vockley CMW (2010) Clinical trials: Curing a critical deficiency in metabolic medicine. Mol Genet Metab 99:244–245PubMedCrossRef
go back to reference Walter JH (2003) L-carnitine in inborn errors of metabolism: what is the evidence? J Inherit Metab Dis 26:181–188PubMedCrossRef Walter JH (2003) L-carnitine in inborn errors of metabolism: what is the evidence? J Inherit Metab Dis 26:181–188PubMedCrossRef
go back to reference Wilcken B (2010) Fatty acid oxidation disorders: outcome and long-term prognosis. J Inherit Metab Dis 33:501–506PubMedCrossRef Wilcken B (2010) Fatty acid oxidation disorders: outcome and long-term prognosis. J Inherit Metab Dis 33:501–506PubMedCrossRef
go back to reference Wilcken B, Haas M, Joy P et al. (2007) Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study. Lancet 369:37–42PubMedCrossRef Wilcken B, Haas M, Joy P et al. (2007) Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study. Lancet 369:37–42PubMedCrossRef
Metadata
Title
Variability in the clinical management of fatty acid oxidation disorders: results of a survey of Canadian metabolic physicians
Authors
Beth K. Potter
Julian Little
Pranesh Chakraborty
Jonathan B. Kronick
Jessica Evans
Julia Frei
Sarah C. Sutherland
Kumanan Wilson
Brenda J. Wilson
Publication date
01-01-2012
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 1/2012
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-011-9352-2

Other articles of this Issue 1/2012

Journal of Inherited Metabolic Disease 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine